Screener / SEC EDGAR /CIK 0001576280 /10-K filed Feb 19, 2026, compared with Feb 20, 2025 /Numbers from the XBRL of the 10-Ks
Health care peers:
Nasdaq Health care · Medical Labs

Guardant Health, Inc. GH

We are a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. 10-K, Item 1

Employees
2,506
Headquarters
Palo Alto, CA
Next results
around Jan 11, 2027
Compare with peers Embed

GH among Health care peers

Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.

Compare
Revenue growth: 32.9%, above 83% of 154 peers (their median 10.4%) REVENUE GROWTH 32.9% · above 83% Gross margin: 65.2%, above 54% of 107 peers (their median 63.4%) GROSS MARGIN 65.2% · above 54% Operating margin: -39.4%, above 12% of 138 peers (their median 10.2%) OPERATING MARGIN -39.4% · above 12% Net margin: -37.9%, above 12% of 153 peers (their median 6.8%) NET MARGIN -37.9% · above 12% FCF margin: -18.2%, above 15% of 144 peers (their median 10.1%) FCF MARGIN -18.2% · above 15%
GH Peer median Below the median

What changed

11 new risk paragraphs. 10-K filed Feb 19, 2026 against Feb 20, 2025.

Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.

Accounting checks

10 checks on the latest 10-K. Checks, not verdicts.

How it works

0facts worth reading about all 10 checks found nothing to note

  • Receivables +25.0% ($110.3M to $137.8M) vs revenue +32.9% ($739.0M to $982.0M), -7.9 pts apart
  • Cash from operations −$184.8M vs net income −$416.3M (FY ending Dec 31, 2025)
  • Inventory +20.8% ($71.1M to $85.9M) vs revenue +32.9% ($739.0M to $982.0M), -12.1 pts apart
7 more checks with nothing to note
  • Same auditor in both 10-Ks: Deloitte & Touche LLP
  • No statement of substantial doubt about going concern
  • No 8-K item 4.02 in the last 2 years
  • No NT 10-K or NT 10-Q in the last 2 years
  • No sentence in the 10-K concludes that controls were not effective because of a material weakness
  • No 8-K item 2.06 in the last 2 years
  • No 8-K item 1.03 in the last 2 years

In their words

11 paragraphs in Risk Factors that were not in the 10-K filed Feb 20, 2025. Quoted as filed.

All 11 new paragraphs
  1. Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
    Changes to FDA Regulation of Companion Diagnostics Could Adversely Affect Our Business and Competitive Position The FDA has proposed reclassifying certain companion diagnostic tests from Class III devices requiring PMA to Class II devices subject to special controls and the 510(k) process. Although the proposal is not final and its…
  2. Item 1A · new paragraph · not in the 10-K filed Feb 20, 2025 10-K, ITEM 1A
    Our increasing usage of artificial intelligence technologies may expose us to operational, regulatory, legal, and reputational risks. We currently utilize, and expect to increasingly rely on, artificial intelligence (AI) in our operations and certain of our products, and we may continue to adopt and integrate AI, including generative AI…

New risk paragraphs, against peers

Latest 10-K of each, Health care companies closest in revenue

Paragraphs in Risk Factors with nothing like them in the company's 10-K the year before. A count of text, not of risk.

Financial performance

Last 4 fiscal years · 10-K XBRL

All years
MetricFY2022FY2023FY2024FY2025
Revenue$449.5M$563.9M$739.0M$982.0M
Net income−$654.6M−$479.4M−$436.4M−$416.3M
Operating cash flow−$309.5M−$325.0M−$239.9M−$184.8M
Free cash flow−$386.9M−$345.5M−$274.9M−$233.1M

Revenue, FY2016 to FY2025

Ten fiscal years, each from its own 10-K · XBRL · USD

$982.0M ▲ 32.9% in FY2025

FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Every number, year by year

Recent filings

5 filings in the last 30 days · SEC EDGAR

All filings

About the company

Guardant Health, Inc., Palo Alto, CA · from the 10-K filed Feb 19, 2026

We are a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. We are transforming patient care by providing critical insights into what drives disease through our advanced blood and tissue tests, real-world data and AI analytics. Our tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer.

Headquarters
Palo Alto, CA
Country
United States
Reports in
USD
Listed on
Nasdaq
Fiscal year ends
December 31
Last results
Nov 5, 2026
Incorporated in
DE

Employees, at the top of the page: "As of December 31, 2025, we had 2,506 employees, 2,490 of which are full-time employees and approximately 2,278 of which are in the U" (10-K). Address and exchange: SEC's company file.

Email alerts

Sources

The 10-K filed Feb 19, 2026 (open at SEC), compared with the 10-K filed Feb 20, 2025. Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.

Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/GH/export.csv") into a cell.

Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.